尼妥珠单抗临床试验研究进展  

Rmemch Progress of Clinical Triak of Nimotumab

作　　者：乔鑫[1] 徐靖源[1] 张彦文[1,2] 

机构地区：[1]天津医科大学药学院,天津300070 [2]天津医科大学继续教育学院,天津300203

出　　处：《药品评价》2011年第22期16-21,共6页Drug Evaluation

摘　　要：尼妥珠单抗（Nimotuzumab，h-R3）是我国第一个表皮生长因子受体为靶点的人源化单克隆抗体药物．能够竞争性结合表皮生长因子受体．抑制肿瘤细胞增殖、促进细胞凋亡．抑制肿瘤血管生成。临床试验显示，其对于多种上皮源肿瘤具有良好的疗效，疾病控制率高．不良反应轻微．患者生存获益显著。Nimotuzumab （h-R3） is the first approved humanized monoclonal antibody targeted the epidermal growth factor receptor in China. It competitively binds epidermal growth factor receptor, promotes apoptosis, and inhibits tumor cell proliferation and tumor angiogenesis. Clinical trials show that nimotuzumab could effectively treat a variety of epithelial tumors with high rate of disease control and mild adverse reactions. Significant survival benefit could be observed in clinical trials.

关 键 词：尼妥珠单抗:表皮生长因子受体(EGFR) 单克隆抗体 临床试验 

分 类 号：R945[医药卫生—微生物与生化药学]